Lakefront Biotherapeutics NV (LKFT) — Net Asset Quality Index
Lakefront Biotherapeutics NV (LKFT) has a Net Asset Quality Index of 96.5% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $3.37 Billion minus total liabilities of $119.06 Million yields net assets of $3.25 Billion. A higher index indicates a stronger, lower-leverage balance sheet. For live market cap and overall valuation, see Lakefront Biotherapeutics NV stock valuation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Lakefront Biotherapeutics NV Net Asset Quality Index Over Time (2022–2025)
This chart shows how Lakefront Biotherapeutics NV's Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of March 2026, the index stands at 96.5%, representing net assets of $3.25 Billion against total assets of $3.37 Billion USD. See what is Lakefront Biotherapeutics NV's book value for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for Lakefront Biotherapeutics NV (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for Lakefront Biotherapeutics NV from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check strategic asset allocation of Lakefront Biotherapeutics NV to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.0% | $3.24 Billion | $3.41 Billion | $170.65 Million | ▲ +24.9 pp |
| 2024 | 70.0% | $2.90 Billion | $4.14 Billion | $1.24 Billion | ▲ +5.9 pp |
| 2023 | 64.2% | $2.80 Billion | $4.36 Billion | $1.56 Billion | ▲ +10.8 pp |
| 2022 | 53.4% | $2.53 Billion | $4.73 Billion | $2.21 Billion | — |